Taysha (TSHA) Form 144 Filed for 27,590 Shares, $79K Value
Rhea-AI Filing Summary
Taysha Gene Therapies (TSHA) filing a Form 144 notifies intent to sell 27,590 shares of common stock through Maxim Group LLC on 08/21/2025 with an aggregate market value of $79,183.30. The shares were acquired as a RSU award and were vested and settled in stock on 08/21/2025, with the stated consideration being the reporting person’s continued service as an employee. The filing reports 272,794,885 shares outstanding and indicates no securities sold by the reporting person in the prior three months.
Positive
- Source of shares disclosed: Shares were acquired via an RSU award and were vested and settled in stock on 08/21/2025.
- Full transaction details provided: Number of shares (27,590), aggregate market value ($79,183.30), broker (Maxim Group LLC), intended sale date (08/21/2025) and shares outstanding (272,794,885) are all specified.
Negative
- None.
Insights
TL;DR: Routine insider sale notice for vested RSUs; size and timing disclosed, no recent sales reported.
The Form 144 indicates a planned sale of 27,590 shares, arising from a vested RSU award settled in stock the same day. The broker is identified as Maxim Group LLC and the intended sale date is 08/21/2025. The filing complies with Rule 144 disclosure requirements and reports no sales by the reporting person over the prior three months. This appears procedural rather than indicative of sudden material developments.
TL;DR: Disclosure documents an employee's sale of vested equity; includes required certification about material nonpublic information.
The filer certifies they are unaware of undisclosed material adverse information and the form notes the RSU origin and vesting/settlement details. The signature and attestation language required under the form are present. No governance or compliance exceptions are stated in the content provided.